U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.1 In December 2017, Janssen entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialize ciltacabtagene autoleucel.CARVYKTI™ is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 In the pivotal CARTITUDE-1 study, one-time treatment with ciltacabtagene autoleucel resulted in deep and durable responses, with 98 percent (95 percent Confidence Interval [CI], 92.7-99.7) of patients with RRMM responding to therapy (98 percent overall response rate [ORR] (n=97).1 Notably, 78 percent (95 percent CI, 68.8-86.1) of the patients achieving this level of response (n=76) experienced a stringent complete response (sCR), a measur...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Actemra | Acute Leukemia | Allergy & Immunology | Amnesia | Anaphylactic Shock | Anemia | Antiviral Therapy | Aphasia | Biotechnology | Bleeding | Brain | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemotherapy | China Health | Constipation | Corticosteroid Therapy | Cough | Cytomegalovirus | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Fungal Infections | Genetics | Guillain-Barr Syndrome | Headache | Health Management | Heart | Heart Transplant | Hematology | Hepatitis | Hepatitis B | Hepatitis C | Hepatitis Vaccine | Hypertension | Immunotherapy | Incontinence | Infectious Diseases | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Learning | Legislation | Leukemia | Lung Transplant | Marketing | Men | Migraine | Myeloma | Neurology | Neuroscience | Oral Cancer | Orthopaedics | Pain | Pain Management | Peripheral Neuropathy | Pharmaceuticals | Physiology | Pneomococcal Vaccine | Pneumonia | Profits and Losses | Pulmonary Hypertension | Respiratory Medicine | Science | Statistics | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Toxicology | Training | Transplants | Universities & Medical Training | Urology & Nephrology | Vaccines | Ventricular Tachycardia | Warnings